IMVT
Immunovant Inc
NASDAQ · Biotechnology
$27.05
+2.99 (+12.43%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.40B | 1.44B | 1.30B |
| Net Income | 261.90M | 339.04M | 251.92M |
| EPS | — | — | — |
| Profit Margin | 18.7% | 23.6% | 19.4% |
| Rev Growth | +1.7% | -7.0% | +15.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.23B | 2.28B | 2.03B |
| Total Equity | 2.96B | 3.29B | 3.14B |
| D/E Ratio | 0.75 | 0.69 | 0.65 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 403.28M | 390.65M | 352.93M |
| Free Cash Flow | 259.22M | 284.01M | 237.35M |